

**OPTIMISATION OF RHEUMATIC DISEASE ASSESSMENTS
IN CLINICAL TRIALS, CLINICAL CARE AND LONG-TERM
DATABASES**

To receive up to 10 CME credits for this activity, complete the evaluation, attestation and post-test answer sheet (minimum passing grade of 70%) and return all pages to:

Joann Carpana
NYU Post-Graduate Medical School
577 First Avenue, #127-B
New York, NY 10016

The submission deadline is March 15, 2014

Please print clearly

Name _____ Degree _____

Mailing address _____

Telephone _____ Fax _____

E-mail _____

Attestation:

I certify that I have completed this enduring material activity.

The actual time I spent on this activity was _____ hours (maximum of 10 hours).

Signature _____ Date of completion _____
[no later than January 13, 2015]

CME Multiple Choice Questions

Post-Test Questions

Please indicate the correct answers to the following questions.

1. Each of the following is true regarding the 14-3-3 η biomarker except:
 - a) 14-3-3 η regulates expression of metalloproteinases
 - b) The citrullinated variant of the 14-3-3 η protein induces an antibody response but not the native protein
 - c) There is minimal correlation between levels of 14-3-3 η and acute phase reactants
 - d) There is an association between a positive test for 14-3-3 η and the severity of rheumatoid arthritis
 - e) Signalling cascades activated by 14-3-3 η may lead to expression of tumour necrosis factor alpha

 2. Approximately what proportion of patients with rheumatoid arthritis has either a positive test for rheumatoid factor or anti-citrullinated peptide antibodies (ACPA):
 - a) 50%
 - b) 60%
 - c) 70%
 - d) 80%
 - e) 90%

 3. Approximately what proportion of patients with rheumatoid arthritis has either an elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP):
 - a) 50%
 - b) 60%
 - c) 70%
 - d) 80%
 - e) 90%

 4. Which of the following is most correct about ultrasound? Ultrasound has been shown to:
 - a) Replace the need for synovial aspiration in the diagnosis of gout
 - b) Provide standardised whole-body synovitis outcomes for RA clinical trials
 - c) Improve the outcomes for patients diagnosed with RA
 - d) Improve clinical certainty in diagnosing RA, when used in combination with the ACR/EULAR classification criteria
 - e) Improve long-term outcomes for painful joints after corticosteroid injections

 5. The simplified disease activity index (SDAI) includes:
 - a) C-reactive protein (CRP)
 - b) Swollen joint count
 - c) Patient global assessment
 - d) All of the above
 - e) B and C but not A

 6. The clinical disease activity index (CDAI) includes:
 - a) C-reactive protein (CRP)
 - b) Swollen joint count
 - c) Patient global assessment
 - d) All of the above
 - e) B and C but not A

 7. The upper limit for Remission according to the RADAI-5 is:
 - a) 0.2
 - b) 0.8
 - c) 1.4
 - d) 2.0
 - e) 2.6

 8. Which 2 of the 7 core data set measures are most efficient to distinguish active from control treatment in clinical trials:
 - a) Physician and patient global assessment
 - b) ESR/CRP and swollen joint count
 - c) Swollen joint count and tender joint count
 - d) Tender joint count and ESR
 - e) ESR and patient global assessment
-

-
9. RAPID3 includes:
- Physical function
 - Pain
 - Patient global assessment
 - All of the above
 - 2 and 3
10. All of the following are true of RAPID3 except:
- Correlated significantly with DAS28 and CDAI
 - Distinguish active from control treatment in clinical trials as efficiently as DAS28 and CDAI
 - Requires 5 seconds on MDHAQ compared to >90 seconds for DAS28 or CDAI
 - Requires physician global assessment
 - Requires information from patient as do DAS28 and CDAI
11. All of the following statements are true of Routine Assessment of Patient Index Data 3 (RAPID3) in SLE except:
- Scores detect clinical improvement in SLE similarly to other rheumatic diseases
 - More feasible than specific SLE indices - can be completed in the waiting area before seeing the rheumatologist
 - Substitute for standard SLE indices in clinical trials and other clinical research
 - Correlated significantly with the specific SLAQ lupus index
 - RAPID3 encourages the patient to be more involved in her/his own care
12. Which of these SLE disease activity indices provides scores for individual organs rather than an overall summary score:
- European Consensus Lupus Activity Measurement (ECLAM)
 - Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI)
 - Systemic Lupus Activity questionnaire (SLAQ)
 - UCSF/JHU Lupus Activity Index (LAI)
 - British Isles Lupus Assessment Group (BILAG)
13. In the NOR-DMARD Data Management system, which information is not registered in the EHR system?
- Joint Counts
 - Adverse Events
 - M-HAQ
 - Acute Phase Reactants
 - RAID
14. What is the measurement construct of the ASAS Health Index?
- To measure quality of life
 - To measure functioning and health in patients with SpA
 - To measure disease activity in patients with SpA
 - To measure severity in patients with musculo-skeletal complaints
 - To measure physical functioning as a single concept
15. Which of the following outcome measures is NOT included in the current definition of inactive disease for JIA?
- Morning stiffness
 - Uveitis
 - Parent's assessment of overall well-being
 - Physician assessment of disease activity
 - Systemic manifestations attributable to JIA
16. Which of the following outcome measures are included in the juvenile arthritis disease activity score (JADAS)?
- Physician assessment of disease activity, Number of active joints, Parent's assessment of overall well-being, ESR
 - Physician assessment of disease activity, Number of swollen joints, Number of tender joints, ESR
 - Physician assessment of disease activity, Number of swollen joints, Number of tender joints, Parent's assessment of overall well-being
 - Physician assessment of disease activity, Number of swollen joints, Number of restricted joints, ESR
 - Physician assessment of disease activity, Number of active joints, Parent's assessment of overall well-being, Physical function (CHAQ)
-

**OPTIMISATION OF RHEUMATIC DISEASE ASSESSMENTS
IN CLINICAL TRIALS, CLINICAL CARE AND LONG-TERM
DATABASES**

Post-Test Answer Sheet

1. a b c d e
2. a b c d e
3. a b c d e
4. a b c d e
5. a b c d e
6. a b c d e
7. a b c d e
8. a b c d e
9. a b c d e
10. a b c d e
11. a b c d e
12. a b c d e
13. a b c d e
14. a b c d e
15. a b c d e
16. a b c d e

OPTIMISATION OF RHEUMATIC DISEASE ASSESSMENTS IN CLINICAL TRIALS, CLINICAL CARE AND LONG-TERM DATABASES

To receive up to 10 CME credits for this activity, complete and submit the evaluation and post-test.
The submission deadline is February 1, 2015

Program Evaluation

Effectiveness Measurement

Based on your participation in this activity, what practice changes do you expect to make in your use of measures and indices to assess the status of patients with rheumatic diseases?

In addition to the changes to practice described above, please indicate any additional changes that you intend to make based on the information received from this activity.

If this education intervention did not fulfill your educational needs, how could future activities address your needs better?

Was the format of the activity appropriate for the educational objectives listed?

- Yes
 No

If no, what format would be better suited for this educational intervention?

- Didactic Lecture
 Case-based discussion
 Debate
 Q/A /Panel Discussion
 Interactive ARS System
 Hands-On Training (simulation/cadaver)
 Enduring Material (online/printed/CD)
 Other

Disclosure / Perception of Bias

Disclosure of commercial support (if any) was clearly communicated.

- Yes
 No
 Not Applicable

Disclosure of relevant financial relationships of faculty were clearly communicated

- Yes
- No

If disclosure of either relationships or commercial support was unclear, how can this information be more clearly presented?

Faculty disclosed when they discussed unlabeled or unapproved uses of drugs or medical devices.

- Yes
- No
- Not Applicable

The activity was free of commercial bias.

- Yes
- No

If you perceived commercial bias in the content or presentation of this activity, please give a detailed account, including the name of the presenter and nature of the perceived bias.

Needs Assessment

Please indicate what knowledge gaps, practice gaps, or patient health issues you have encountered in your own practice or in the profession that the NYU Post-Graduate Medical School could address with continuing medical education initiatives.

Activity Preference

What is your preference for CME activity format?

- Live Program
- Web-Based Enduring Materials
- DVD Enduring Materials
- Printed Enduring Materials

Overall Activity Comments
